Iterum Therapeutics plc (ITRMF): Nasdaq/NYSE listing notice — Iterum Therapeutics receives Nasdaq delisting notice for equity deficit of $6.4M

Iterum Therapeutics plc

Stockholders' equity deficit of $6.4M as of Dec 31, 2023, below Nasdaq's $2.5M minimum.
Company must submit a compliance plan by May 20, 2024; Nasdaq may extend deadline to Sept 30, 2024.
If plan is rejected or compliance not regained, delisting proceedings may begin with appeal rights.
Iterum is evaluating options to resolve the deficiency; listing continues for now.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Iterum Therapeutics plc received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

April 3, 2024, Iterum Therapeutics plc (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), because (i) the stockholders’ equity (deficit) of the Company of ($6,403,000) as of December 31, 2023, as reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, was below the minimum stockholders’ equity requirement of $2,500,000 and (ii) the Company did not, as of April 3, 2024, meet the alternatives standards of market value of listed securities or net income from c

View on SEC.gov

Browse all listing & compliance notices →

Iterum Therapeutics plc filing history →

Source: SEC EDGAR

accession 0000950170-24-042288

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.